Xeris Biopharma(US:XERS) ZACKS·2025-10-20 17:00Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Xeris Biopharma (XERS) - Xeris Biopharma currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), which is associated with a historical outperformance when combined with a strong Style Score [4] Price Performance - XERS shares have increased by 15.64% over the past week, while the Zacks Medical - Drugs industry remained flat [6] - Over the past month, XERS has shown a price change of 19.69%, significantly outperforming the industry's 0.1% [6] - In the last quarter, XERS shares rose by 84.06%, and over the past year, they have gained 201.96%, compared to the S&P 500's increases of 6.14% and 15.41%, respectively [7] Trading Volume - The average 20-day trading volume for XERS is 2,208,657 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for XERS has increased, while none have decreased, leading to a consensus estimate improvement from -$0.03 to -$0.01 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive sentiment [10] Conclusion - Considering the strong price performance, trading volume, and positive earnings outlook, Xeris Biopharma is positioned as a promising momentum pick with a 2 (Buy) rating and a Momentum Score of A [12]